Bupropion SR
Zyban
- Dosage form
- Tablet
- Available strengths
- 150 mg
- Drug class
- Aminoketone antidepressant (norepinephrine-dopamine reuptake inhibitor) -- sustained-release formulation used as a smoking-cessation aid
- Common brand
- Zyban
Clinical overview. Bupropion SR (Zyban) is a sustained-release, twice-daily formulation of bupropion licensed specifically as a smoking-cessation aid -- distinct from the once-daily Wellbutrin XL formulation used for depression. It reduces nicotine cravings and withdrawal by weakly inhibiting dopamine and norepinephrine reuptake. Treatment is titrated over the first week and typically continued for 7 to 12 weeks, started 1 to 2 weeks before the target quit date. Its most important risk is a dose-related increase in seizures, so it is contraindicated in patients with a seizure disorder or a current or past eating disorder.
Indication
Common therapeutic uses
- Bupropion SR (Zyban) is indicated as an aid to smoking cessation treatment, used together with behavioural counselling and support.
- This sustained-release, twice-daily formulation and dosing schedule is specific to the smoking-cessation indication and differs from the once-daily extended-release (XL) formulation used to treat major depressive disorder -- the two are not interchangeable on the same dosing schedule.
Pregnancy
Risk assessment and monitoring considerations
- Bupropion has not been thoroughly studied in controlled trials during pregnancy; use only if the anticipated benefit of smoking cessation is judged to outweigh the potential risk to the fetus.
Breastfeeding
Infant exposure considerations
- Bupropion and its metabolites pass into human breast milk. A decision should be made whether to continue breastfeeding or continue bupropion, weighing the importance of smoking cessation to the patient.
Geriatrics
Dosing and tolerability considerations
- Older adults may have reduced clearance of bupropion and increased sensitivity to its central nervous system effects; use caution and consider the lowest effective dose.
Pediatrics
Use in children and adolescents
- Not established as safe or effective in patients under 18 years of age for smoking cessation.
Dosage & Administration
Practical dosing and administration
- Start 1-2 weeks before the target quit date, while the patient is still smoking.
- Days 1-3: 150 mg PO once daily in the morning.
- Day 4 onward: 150 mg PO twice daily, with doses at least 8 hours apart -- do not exceed a single dose of 150 mg, and do not exceed 300 mg/day.
- Continue for 7-12 weeks; longer maintenance may be considered individually for patients who have quit and are judged to be at high relapse risk.
- If a dose is missed, skip it entirely and resume at the next scheduled time -- do not double up, since this raises seizure risk.
- Tablets must be swallowed whole and never crushed, chewed, or divided, since disrupting the sustained-release coating can cause rapid release and increase seizure/overdose risk.
- In mild-to-moderate hepatic impairment, use with caution and consider a reduced dose/frequency; in severe hepatic impairment, bupropion is not recommended, and if used, the dose should not exceed 150 mg every other day.
- In renal impairment, consider a reduced dose and/or frequency due to the potential for drug accumulation.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Overdose can cause seizures (including status epilepticus), hallucinations, loss of consciousness, tachycardia, and ECG changes (QRS/QTc prolongation, arrhythmias); fatalities have been reported, more often with mixed-drug overdose.
- Management is supportive: airway/breathing/circulation support, continuous cardiac monitoring, and EEG monitoring for the first 48 hours after a significant ingestion; activated charcoal may be given; inducing vomiting is not recommended. Seizures are generally managed with intravenous benzodiazepines. There is no specific antidote.
Common side effects
Frequently reported tolerability concerns
- Insomnia (dosing in the early morning and mid-afternoon, avoiding doses close to bedtime, can reduce this).
- Dry mouth.
- Dizziness.
- Restlessness or agitation.
- Headache.
- Nausea.
- Constipation.
- Tremor.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Seizures -- dose-related; do not exceed the maximum recommended dose or single-dose limit.
- New or worsening depression, agitation, suicidal thoughts, or other mood/behavioural changes -- can occur even without a prior psychiatric history; monitor closely, especially in the first weeks of treatment.
- Severe hypertension, particularly when combined with nicotine replacement therapy -- monitor blood pressure if combination therapy is used.
- Severe allergic reactions (anaphylaxis, angioedema) and severe cutaneous reactions (Stevens-Johnson syndrome, DRESS) have been reported.
- Psychosis, hallucinations, or mania, particularly in patients with a history of bipolar disorder or psychotic illness.
- Seek urgent medical attention for a seizure, signs of a severe allergic reaction, chest pain, or new or worsening suicidal thoughts.
Use with caution
Situations requiring closer assessment
- Use with caution, at a reduced dose, in patients with any factor that lowers the seizure threshold: head trauma, CNS tumour, severe hepatic impairment, heavy alcohol use, or concurrent use of other drugs that lower seizure threshold (antipsychotics, other antidepressants, systemic corticosteroids, quinolone antibiotics, theophylline).
- Use with caution in patients with cardiovascular disease, including recent myocardial infarction or unstable heart disease.
- Use with caution in older adults and in hepatic or renal impairment, starting at a reduced dose.
- Use caution when driving or operating machinery until the effect on alertness and coordination is known.
Contraindications
Situations where therapy may be inappropriate
- Current seizure disorder or any history of seizures.
- Current or past diagnosis of anorexia nervosa or bulimia nervosa (higher seizure risk in this population).
- Abrupt discontinuation of alcohol, benzodiazepines, or other sedative-hypnotics (increases seizure risk).
- Concurrent use of a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days.
- Concurrent use of any other medication containing bupropion (including bupropion prescribed for depression) -- do not combine.
- Known hypersensitivity to bupropion or any component of the formulation.
Drug interactions
Clinically relevant combinations
- Potent CYP2D6 inhibitor -- may raise levels of drugs metabolized by this pathway and reduce the effectiveness of drugs requiring CYP2D6 activation (e.g., codeine, tamoxifen).
- Do not use with MAOIs (risk of hypertensive crisis, mania, hyperpyrexia); allow a 14-day interval on either side of switching.
- Use with caution alongside other drugs that lower the seizure threshold.
- Combining with nicotine replacement therapy may raise blood pressure -- monitor if used together.
Food interactions
Meal-related administration
- No clinically significant food interaction; may be taken with or without food.
Time of administration
Practical scheduling
- Twice daily, at least 8 hours apart, with the first dose in the early morning; avoid a second dose close to bedtime to reduce insomnia risk.
Storage
Product handling
- Store at room temperature, out of reach and sight of children.
Patient take-away
Key counselling points for a quick closing summary
- Start this medicine 1-2 weeks before your quit date, while you are still smoking -- it needs time to build up before it helps you quit.
- Take your two daily doses at least 8 hours apart, and never take a dose close to bedtime if you have trouble sleeping.
- Swallow tablets whole -- never crush, chew, or split them.
- Seek urgent care for a seizure, a severe allergic reaction, or new or worsening thoughts of self-harm.
- Avoid alcohol and tell your pharmacist about all your other medicines, since bupropion has a number of important drug interactions.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.